Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03495102 · ClinicalTrials.gov registry record · Phase 3
A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,842
- Enrollment target
NCT03495102 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,842 participants.
The verdict
NCT03495102, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,842 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of investigational doses of once weekly dulaglutide when added to metformin in participants with type 2 diabetes with inadequate blood sugar control.
Interventions
- DRUG Dulaglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,842 participants |
| Start Date | 2018-04-05 |
| Est. Completion | 2019-10-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03495102
The ClinicalTrials.gov registry entry for NCT03495102 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,842 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dulaglutide is the first listed.
NCT03495102 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03495102 about?
NCT03495102 is a clinical study titled "A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes". The purpose of this study is to evaluate the efficacy and safety of investigational doses of once weekly dulaglutide when added to metformin in participants with type 2 diabetes with inadequate blood sugar control.
What is the current status of trial NCT03495102?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,842 participants. The study started on 2018-04-05. Estimated completion is 2019-10-10.
What interventions are being tested in trial NCT03495102?
The interventions under investigation include: Dulaglutide (DRUG).
Who is sponsoring clinical trial NCT03495102?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.